<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" type="text/css" href="css/style-manual.css">
    <link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
    <script src="js/script.js"></script>
</head>
<body>
<!--Omaglip-------------------------------------------------------->
<div class="bodyDiv" id="idOmaglip">
    <div class="w3-container w3-center w3-animate-left">
        <h2 class="mango">Omaglip</h2>
    </div>
<b>Product Orientation & Presentation:</b><br>
  
<table class="table1">
<tr>
    <td>Brand Name:</b><br>
Omaglip
	</td>
</tr>

<tr>
    <td><b>Generic & Strength:</b><br>
Omarigliptin INN 12.5 & 25 mg Tablets.
	</td>
</tr>
  
 <tr>
     <td><b>
	Dosage Form:</b><br>
Tablet.
	 </td>
</tr>
	 
<tr>
    <td><b>Therapeutic Class:</b><br>
DPP-4 Inhibitor/ anti- diabetic
	</td>
</tr>
 
<tr>
    <td><b>Sub Therapeutic class:</b><br>

	</td>
</tr>
		 
<tr>
    <td><b>Commercial Pack:</b><br>


	12.5mg= 4's<br>
	25mg= 4's
	</td>
</tr>
	 
<tr>
    <td><b>Price (TP):</b><br>
 
		12.5mg= 80.00 Bdt<br>
	25mg= 140.00 Bdt
	<br>
    </td>
</tr>	
	 
<tr>
    <td><b>Flavour:</b><br>
.
	</td>
</tr>
  
<tr>
    <td><b>Indication:</b><br>
Indicated for the treatment of adults with type 2 diabetes. 
	</td>
</tr>
  
<tr>
    <td><b>Pregnancy:</b><br>
Safety and efficacy of this drug in pregnancy has not been established.

    </td>
</tr>

<tr>
    <td><b>Lactation:</b><br>
Breastfeeding should be avoided.
    </td>
</tr>

<tr>
    <td><b>Children:</b><br>
Safety and efficacy of this drug in children has not been established.
    </td>
</tr>
  
<tr>
    <td><b>Brand Name Justification:</b><br>
  
	</td>
</tr>

<tr>
    <td><b>Brand Slogan:</b><br>
A novel once-Weekly Medication.
    </td>
</tr>

<tr>
    <td><b>Dosage & Administration:</b><br>

&#x2022; The usual recommended dose is 25 mg once weekly as monotherapy.<br>
The dosage should be reduced to 12.5 mg once weekly in patients with severe renal dysfunction and end-stage renal failure. 
    </td>
</tr>

<tr>
    <td><b>Key Selling Points:</b><br>

&#x2022; Maintains glucose homeostasis.<br>

&#x2022; Ensures maximum & sustained lowering of glucose.<br>

&#x2022; Provides the greatest glucose lowering efficacy with good tolerability.
    <br>
    </td>
</tr>

<tr>
    <td><b>Target Doctor:</b><br>

&#x2022; 
    </td>
</tr>

<tr>
    <td><b>Side effects:</b><br>

Hypoglycemia, acute pancreatitis, bowel obstruction and intestinal obstruction. Other side effects are 
gastrointestinal problem, constipation, diarrhoea, skin and subcutaneous tissue disorders.
    </td>
</tr>

<tr>
    <td colspan="4">
---
    </td>
</tr>

</table>
<br><br>



Short Detailing of <b>Omaglip</b>:<br>
আপনি জানেন T2DM patient দের জন্য recently world - wide available Omarigliptin যা ensure করে Once -
weekly dosing with good tolerability ।<br>

Omarigliptin হলো Potent , Selective DPP - 4 inhibitor । Omarigliptin Longer half - life
( 120 hr . ) ensure করার মাধ্যমে Once - weekly dose ensure করে থাকে।<br>

Omarigliptin প্রথম ডোজে 98 % DPP - 4 inhibition করে এবং প্রথম ডোজের 7 দিন পরে 83 % DPP - 4 inhibition করে।<br>


নাভানা ফার্মা T2DM patient দের জন্য better treatment drug হিসেবে <b>Omaglip</b> যা Omarigliptin 12.5mg & 25mg
এর preparation that indicates "A Novel once - weekly medication for T2DM”। <br>

<b>Omaglip</b> ( Omarigliptin ) দুই ভাবে কাজ করে থাকে :<br>
1. Pancreas থেকে ইনসুলিন এর secretion কে বাড়ায়।<br>
2. Liver থেকে Glucagon এর secretion কে কমায়।<br>

<b>Omaglip</b> এর half - life 120 hr .। Clinical Study থেকে দেখা যাচ্ছে <b>Omaglip</b> 12 - weeks এ
Diabetes markers যেমন HbA1c -0.72 %, FPG -1.3mmol/ L এবং PPG -2.5mmol/ L reduces করেছে। <b>Omaglip</b>
renal patients দের জন্য ভালো একটি options. <b>Omaglip</b> body weight এর উপরে কোনো ভূমিকা রাখে না।
এছাড়া <b>Omaglip</b> 78 সপ্তাহ পর্যন্ত well - tolerated।<br>

Sir / Madam : Considering all benefits, may I expect 2 Rx daily in favor of <b>Omaglip</b>?<br>

Thank you Sir / Madam.<br><br>


<b>Prescribing Information:</b><br>

<b>Composition</b><br>
Omaglip 12.5 Tablet<br>
Each film coated tablet contains Omarigliptin INN 12.5 mg.<br>
Omaglip 25 Tablet:<br>
Each film coated tablet contains Omarigliptin INN 25 mg.<br>

<b>Pharmacology:</b><br>
Omarigliptin is a long-acting inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 rapidly degrades 
incretin hormones. Incretins lower blood glucose concentrations in response to a meal by increasing insulin 
and decreasing glucagon levels in a glucose-dependent manner. Thus, omarigliptin's mechanism of action 
augments the action of incretin hormones. Omarigliptin is cleared by excretion into the urine. 
It is structurally different from currently available once daily dosing DPP-4 inhibitors. 
It is rapidly absorbed after administration, with time to maximum concentration ranging from 0.5 to 4.0 hours.
 The terminal half-life of Omarigliptin was greater than 100 hours which allows for once-weekly administration. 
 <br>
 <b>Indication:</b><br>
 Omarigliptin is an oral, once-weekly DPP-4 inhibitor indicated for the treatment of adults with type 2 diabetes. 
 <br>
 <b>Dosage & Administration:</b><br>
 The usual recommended dose is 25 mg once weekly as monotherapy. The dosage should be reduced to 12.5 mg once 
 weekly in patients with severe renal dysfunction and end-stage renal failure. 
 <br>
<b>Missed dose:</b><br>
If a dose is missed, it should be taken as soon as possible and then the regular weekly dosing schedule 
should be followed. Two doses should not be taken at the same time or as directed by the physicians. 
<br>
<b>Contraindications:</b><br>
Patients with a history of hypersensitivity to any of the components of this drug. 
<br>
<b>Warnings & Precautions:</b><br>
Since this drug is mainly excreted by the kidneys, therefore dose should be adjusted in patients with severe 
renal impairment, hemodialysis or peritoneal dialysis and end-stage renal failure. Other antidiabetic drugs 
(in particular, insulin preparation or sulfonylurea) should be used with caution in combination with 
Omarigliptin as they may cause hypoglycemia. 
<br>
<b>Side Effects:</b><br>
Hypoglycemia, acute pancreatitis, bowel obstruction and intestinal obstruction. Other side effects are 
gastrointestinal problem, constipation, diarrhoea, skin and subcutaneous tissue disorders. 
<br>
<b>Use in Pregnancy & Lactation:</b><br>
Safety and efficacy of this drug in pregnancy has not been established.
Breastfeeding should be avoided. 
<br>
<b>Use in Children & Adolescents:</b><br>
Safety and efficacy of this drug in children has not been established. 

<b>Drug Interactions:</b><br>
Omarigliptin interacts Metformin, Glimepiride, Oral contraceptives & Atorvastatin. 
<br>
<b>Overdosage:</b><br>
Overdosage may cause Nasopharyngitis. 
<br>
<b>Storage:</b><br>
Store below 30°C, keep away from light and in a dry place. Keep all medicines out of the reach of children. 
<br>
<b>Packing: Omaglip 12.5 Tablet:</b><br>
Each box contains 1X4 tablets in Alu-Alu blister pack and an insert.<br>
Omaglip 25 Tablet: Each box contains 1X4 tablets in Alu-Alu blister pack and an insert.<br><br>
</div>
<footer>
    <p>© 2024 Md. Nurullah. All rights reserved.</p>
</footer>
<center><div class="ovalEnd">The End-Omaglip</div></center><!--End Line---->
</body>
</html>